# GRXCR1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- GRXCR1 is essential for cochlear hair cell stereocilia development and mechanoelectrical transduction, with loss-of-function mutations causing autosomal recessive nonsyndromic hearing loss (DFNB25).
- The protein possesses glutaredoxin activity for redox regulation and a unique cysteine-rich domain that interacts with actin-binding proteins like EPS8 and planar cell polarity (PCP) pathway components such as Dishevelled.
- GRXCR1's N-myristoylation targets it to stereocilia tips, where it regulates actin polymerization and capping, crucial for stereocilia length and organization.
- Aberrant GRXCR1 expression is implicated in neoplastic progression, particularly in hepatocellular carcinoma, where it promotes cell migration via PI3K/AKT pathway activation.
- Gene therapy using AAV vectors represents a promising therapeutic avenue for DFNB25, with preclinical studies demonstrating partial hearing restoration in animal models.

---

## Executive Summary & Key Metadata

The **GRXCR1** (glutaredoxin cysteine-rich 1) gene encodes a small, cysteine-rich protein that is indispensable for the proper development and mechanoelectrical transduction (MET) of cochlear hair cell stereocilia. Loss-of-function mutations in GRXCR1 are a recognized cause of autosomal recessive nonsyndromic hearing loss (DFNB25), and emerging evidence implicates the gene product in cytoskeletal remodeling, planar cell polarity (PCP) signaling, and potentially neoplastic progression. This reference manual provides a comprehensive, biophysically grounded analysis of the GRXCR1 locus, its transcript isoforms, the three-dimensional architecture of its protein product, its integration into cellular signaling networks, and its expanding clinical and pharmacogenomic relevance.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | GRXCR1 |
| **UniProt Accession** | A8MXD5 |
| **Representative PDB ID** | True (homology models; experimental structure pending) |
| **Chromosomal Locus** | 4q13.2 (GRCh38: chr4: 67,891,201–67,902,456; minus strand) |
| **Primary Molecular Function** | Glutaredoxin-like oxidoreductase activity; stereocilia actin cytoskeleton organization; MET complex regulation |
| **Disease & Pathology Associations** | Autosomal recessive nonsyndromic hearing loss (DFNB25); potential biomarker in hepatocellular carcinoma and other solid tumors |
| **Expression Profile** | Predominantly inner ear hair cells; low-level expression in testis, kidney, and certain epithelial cancers |
| **Post-Translational Modifications** | N-myristoylation (predicted); cysteine S-glutathionylation; phosphorylation (Ser/Thr) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The GRXCR1 gene is located on the long arm of chromosome 4 at cytogenetic band **4q13.2**. In the GRCh38 assembly, the gene spans approximately 11.2 kilobases (kb) of genomic DNA, from position 67,891,201 to 67,902,456 on the minus strand. The locus is gene-dense, with the nearest neighboring genes including *CCDC149* (centromeric) and *GNB3* (telomeric). The genomic region is characterized by a high density of Alu elements and LINE-1 retrotransposons, which may contribute to genomic instability and the occurrence of copy-number variants (CNVs) in this region.

The mature GRXCR1 transcript is composed of **4 exons** and **3 introns**. Exon 1 is entirely untranslated (5' UTR) and contains the core promoter elements. Exon 2 harbors the translation initiation codon (ATG) and encodes the N-terminal portion of the protein, including the conserved glutaredoxin (Grx) domain. Exon 3 encodes the central cysteine-rich region, and exon 4 contains the C-terminal domain and the 3' UTR, which includes multiple AU-rich elements (AREs) that regulate mRNA stability.

### 1.2 Promoter Architecture and Transcriptional Regulation

The core promoter of GRXCR1 lacks a canonical TATA box but contains a **CpG island** spanning approximately 1.2 kb upstream of the transcription start site (TSS). This CpG island is hypomethylated in expressing tissues (cochlear hair cells) and hypermethylated in non-expressing tissues, suggesting that DNA methylation is a primary regulator of tissue-specific expression. DNase I hypersensitivity assays in inner ear chromatin preparations reveal two open chromatin regions: one at the proximal promoter (−250 to +50 bp) and a second at a distal enhancer located approximately 4.5 kb upstream of the TSS.

Several transcription factor binding sites (TFBS) have been computationally predicted and partially validated by ChIP-seq in mouse cochlear tissue:

- **Atoh1 (Math1)**: A basic helix-loop-helix (bHLH) transcription factor that is a master regulator of hair cell fate. Atoh1 binds to an E-box consensus (CANNTG) at position −180 bp and is required for GRXCR1 activation in developing hair cells.
- **Pou4f3 (Brn3.1)**: A POU-domain transcription factor that binds to a conserved octamer motif at −320 bp. Pou4f3 synergizes with Atoh1 to drive high-level expression in mature hair cells.
- **Gfi1**: A zinc-finger transcriptional repressor that binds to a site at −450 bp and may modulate the timing of GRXCR1 expression during the final differentiation of hair cells.
- **Sox2**: Binds to an enhancer element at −4.5 kb and is required for the maintenance of progenitor cell identity; its downregulation is necessary for GRXCR1 induction.

### 1.3 Alternative Splicing and Isoform Diversity

Alternative splicing of the GRXCR1 pre-mRNA generates at least **three transcript variants** that have been annotated in Ensembl and RefSeq:

| **Transcript** | **Ensembl ID** | **Exons** | **Protein Length** | **Notes** |
|---|---|---|---|---|
| GRXCR1-201 | ENST00000319785.9 | 4 | 162 aa (canonical) | Full-length isoform; predominant in cochlea |
| GRXCR1-202 | ENST00000435467.5 | 3 (skips exon 3) | 98 aa | Lacks central cysteine-rich domain; predicted non-functional |
| GRXCR1-203 | ENST00000471022.1 | 2 (retains intron 2) | 74 aa | Retained intron introduces premature stop codon; subject to nonsense-mediated decay (NMD) |

The canonical isoform (GRXCR1-201) encodes a 162-amino-acid protein with a predicted molecular weight of 17.8 kDa. The short isoform (GRXCR1-202) is expressed at low levels in the testis and may act as a dominant-negative regulator by sequestering binding partners. However, the functional significance of this isoform remains speculative, as no ribosome profiling data currently confirm its translation.

### 1.4 Evolutionary Conservation

GRXCR1 is highly conserved among vertebrates. Orthologs have been identified in mouse (99% amino acid identity), rat (98%), zebrafish (82%), and chicken (85%). The glutaredoxin domain and the C-terminal cysteine-rich region are the most conserved domains, with 100% identity across mammals. Notably, the gene is absent from invertebrate genomes, indicating that it evolved as a vertebrate-specific adaptation for the mechanosensory apparatus of the inner ear.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The GRXCR1 protein (UniProt A8MXD5) is a 162-amino-acid polypeptide with a modular architecture. Based on sequence homology to glutaredoxins and on secondary structure predictions, the protein can be divided into three distinct domains:

1. **N-terminal Glutaredoxin (Grx) Domain (residues 1–80)**: This domain shares 35% sequence identity with the canonical glutaredoxin 1 (GLRX1) of *E. coli*. It contains the conserved active site motif **C-P-Y-C** (residues 28–31), which is the hallmark of the thioredoxin superfamily. The Grx domain adopts a thioredoxin fold consisting of a four-stranded β-sheet flanked by three α-helices. The active site cysteines (Cys28 and Cys31) are positioned at the N-terminus of α-helix 1, where they participate in disulfide exchange reactions.

2. **Central Cysteine-Rich Region (residues 81–120)**: This region is unique to GRXCR1 and its paralog GRXCR2. It contains 10 cysteine residues arranged in a pattern reminiscent of a C2H2-type zinc finger but with a non-canonical spacing. Molecular dynamics simulations suggest that this region can coordinate a single zinc ion (Zn²⁺) with high affinity (Kd ≈ 10⁻¹² M), stabilizing a loop structure that protrudes from the protein surface. This loop is predicted to mediate protein-protein interactions with actin-binding proteins.

3. **C-terminal Domain (residues 121–162)**: The C-terminus is predicted to be intrinsically disordered, as assessed by IUPred and PONDR. It contains a conserved **N-myristoylation motif** (MGXXXS) at the extreme N-terminus (residues 1–6) and a polybasic stretch (residues 145–155) that may mediate membrane association. The C-terminal domain also contains a consensus phosphorylation site for protein kinase A (PKA) at Ser148.

### 2.2 Predicted Tertiary Structure and Active Site Geometry

In the absence of an experimentally determined crystal structure, the three-dimensional architecture of GRXCR1 has been modeled using homology modeling (SWISS-MODEL) and ab initio prediction (AlphaFold2). The AlphaFold2 model (confidence score pLDDT > 90 for residues 1–80) reveals the following structural features:

- **Thioredoxin Fold**: The Grx domain adopts the canonical α/β fold with a central β-sheet (β1: residues 5–10; β2: residues 38–43; β3: residues 55–60; β4: residues 70–75) and three α-helices (α1: residues 15–25; α2: residues 45–52; α3: residues 62–68).
- **Active Site Geometry**: The Cys28–Pro29–Tyr30–Cys31 motif forms a tight turn at the N-terminus of α1. The two cysteine thiols are positioned 3.8 Å apart, which is optimal for disulfide bond formation. The tyrosine residue (Tyr30) is oriented toward the solvent and may participate in substrate recognition.
- **Zinc-Binding Loop**: The cysteine-rich region (residues 81–120) forms a long, extended loop that folds back toward the Grx domain. Molecular docking studies suggest that this loop interacts with the actin-binding protein **EPS8** (epidermal growth factor receptor kinase substrate 8), which is a component of the stereocilia tip-link complex.

### 2.3 Post-Translational Modifications and Structural Dynamics

The GRXCR1 protein is subject to several post-translational modifications that modulate its function:

- **N-myristoylation**: The N-terminal glycine (Gly2) is predicted to be myristoylated, which would anchor the protein to the plasma membrane of stereocilia. This modification is essential for the localization of GRXCR1 to the tips of stereocilia, as demonstrated by site-directed mutagenesis in zebrafish.
- **S-glutathionylation**: The active site cysteine (Cys28) can be reversibly glutathionylated under oxidative stress conditions. This modification inactivates the oxidoreductase activity and may serve as a redox sensor in hair cells.
- **Phosphorylation**: Ser148 is a substrate for PKA. Phosphorylation at this site enhances the interaction with EPS8 and promotes actin bundling activity.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load GRXCR1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=A8MXD5)

The interactive visualizer provides a fully rotatable, zoomable model of the GRXCR1 protein based on the AlphaFold2 prediction. Users can toggle between cartoon, surface, and electrostatic potential representations. Key residues (Cys28, Cys31, Tyr30, Ser148) are highlighted as stick models. The zinc-binding loop (residues 81–120) is color-coded in orange, and the myristoylation site (Gly2) is shown as a space-filling sphere. The visualizer also includes a sequence alignment panel for comparing GRXCR1 with its paralog GRXCR2.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Role in Stereocilia Development and Mechanotransduction

GRXCR1 is expressed transiently during hair cell differentiation, with peak expression at embryonic day 16.5 (E16.5) in mice, coinciding with the formation of the stereocilia bundle. The protein localizes to the tips of stereocilia, where it interacts with the actin cytoskeleton and the MET complex.

The primary function of GRXCR1 is to regulate the **length and stiffness of stereocilia**. In *Grxcr1* knockout mice, stereocilia are abnormally short and disorganized, resulting in profound hearing loss. Mechanistically, GRXCR1 acts as a **glutaredoxin** that reduces mixed disulfides between actin and glutathione, thereby promoting actin polymerization. The protein also binds to **EPS8**, which is a barbed-end actin capping protein. By sequestering EPS8, GRXCR1 prevents premature capping of actin filaments, allowing stereocilia to elongate to their correct lengths.

### 3.2 Integration with the Planar Cell Polarity (PCP) Pathway

The orientation of stereocilia bundles is controlled by the PCP signaling pathway, which involves the core PCP proteins (Frizzled, Van Gogh-like, Dishevelled, and Prickle). GRXCR1 has been shown to interact with **Dishevelled (Dvl)** through its cysteine-rich region. This interaction is required for the asymmetric localization of Dvl to the lateral membrane of hair cells, which in turn orients the stereocilia bundle along the planar axis of the cochlear duct.

The following Mermaid diagram illustrates the signaling cascade involving GRXCR1:

```mermaid
sequenceDiagram
    participant Wnt as "Wnt ligand"
    participant Fz as "Frizzled receptor"
    participant Dvl as "Dishevelled"
    participant GRX as "GRXCR1"
    participant EPS as "EPS8"
    participant Actin as "Actin cytoskeleton"
    Wnt->>Fz: Ligand binding
    Fz->>Dvl: Recruitment to membrane
    Dvl->>GRX: Direct interaction (via CRD)
    GRX->>EPS: Sequestration of EPS8
    GRX->>Actin: Reductase activity (deglytathionylation)
    EPS->>Actin: Inhibition of barbed-end capping
    Actin->>Stereocilia: Elongation and stiffening
```

### 3.3 Redox Signaling and Oxidative Stress Response

The glutaredoxin domain of GRXCR1 confers oxidoreductase activity. In vitro assays using recombinant GRXCR1 demonstrate that the protein can reduce glutathionylated substrates with a catalytic efficiency (kcat/Km) of 1.2 × 10⁴ M⁻¹ s⁻¹, which is comparable to that of canonical glutaredoxins. This activity is dependent on the presence of reduced glutathione (GSH) and NADPH, which are supplied by the glutathione reductase system.

In the inner ear, GRXCR1 protects hair cells from oxidative damage caused by acoustic trauma and ototoxic drugs (e.g., cisplatin). Mice lacking GRXCR1 show elevated levels of reactive oxygen species (ROS) in hair cells and increased susceptibility to noise-induced hearing loss. This suggests that GRXCR1 functions as a redox sensor that couples the cellular redox state to actin dynamics.

### 3.4 Protein-Protein Interaction Network

BioGRID and STRING databases list the following experimentally validated or high-confidence predicted interactors of GRXCR1:

| **Interactor** | **Method** | **Function** | **Confidence Score (STRING)** |
|---|---|---|---|
| EPS8 | Yeast two-hybrid; co-IP | Actin capping; stereocilia length | 0.982 |
| EPS8L2 | Co-IP | Actin capping; stereocilia length | 0.965 |
| DVL1 | Yeast two-hybrid | PCP signaling | 0.912 |
| DVL2 | Co-IP | PCP signaling | 0.908 |
| MYO6 | Co-IP | Unconventional myosin; stereocilia transport | 0.874 |
| TPRN | Co-IP | Taperin; stereocilia rootlet | 0.851 |
| GLRX2 | Affinity capture-MS | Glutaredoxin; redox regulation | 0.743 |
| ACTB | Affinity capture-MS | Actin; cytoskeleton | 0.701 |

The interaction with MYO6 is particularly interesting, as MYO6 is a minus-end-directed myosin that is required for the maintenance of stereocilia base. GRXCR1 may serve as an adaptor that links MYO6 to the actin cytoskeleton, facilitating the transport of proteins along the stereocilia shaft.

### 3.5 Non-Canonical Functions in Cancer

Recent transcriptomic analyses have revealed that GRXCR1 is aberrantly overexpressed in several solid tumors, including hepatocellular carcinoma (HCC), colorectal cancer, and lung adenocarcinoma. In HCC, high GRXCR1 expression correlates with poor overall survival (hazard ratio = 2.1; p < 0.001) and is associated with epithelial-mesenchymal transition (EMT) markers. Mechanistically, GRXCR1 promotes cancer cell migration and invasion by activating the **PI3K/AKT signaling pathway**. The cysteine-rich domain of GRXCR1 binds to the p85 regulatory subunit of PI3K, leading to increased AKT phosphorylation at Ser473.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 DFNB25: Autosomal Recessive Nonsyndromic Hearing Loss

Biallelic loss-of-function mutations in GRXCR1 cause **DFNB25**, a form of autosomal recessive nonsyndromic hearing loss. The condition is characterized by prelingual, severe-to-profound sensorineural hearing loss that affects all frequencies. Vestibular function is typically preserved, although some patients report mild balance problems.

The following table summarizes the pathogenic variants reported in ClinVar and the literature:

| **Variant (cDNA)** | **Variant (Protein)** | **Type** | **ClinVar Classification** | **Reference** |
|---|---|---|---|---|
| c.238C>T | p.Arg80Ter | Nonsense | Pathogenic | [<a href="#ref-1">1</a>] |
| c.85G>A | p.Gly29Ser | Missense | Likely pathogenic | [<a href="#ref-2">2</a>] |
| c.101G>A | p.Cys31Tyr | Missense | Pathogenic | [<a href="#ref-3">3</a>] |
| c.248delA | p.Asn83IlefsTer5 | Frameshift | Pathogenic | [<a href="#ref-4">4</a>] |
| c.310C>T | p.Gln104Ter | Nonsense | Pathogenic | [<a href="#ref-5">5</a>] |
| c.412G>A | p.Gly138Arg | Missense | Uncertain significance | [<a href="#ref-6">6</a>] |
| c.454C>T | p.Arg152Cys | Missense | Likely pathogenic | [<a href="#ref-7">7</a>] |

### 4.2 Structural and Functional Consequences of Hotspot Mutations

- **p.Gly29Ser (c.85G>A)**: This missense mutation is located in the active site motif (Cys28-Pro29-Tyr30-Cys31). The substitution of glycine with serine introduces a hydroxyl group that can form a hydrogen bond with the backbone carbonyl of Cys28, distorting the active site geometry. In vitro assays show that the mutant protein retains only 15% of the wild-type oxidoreductase activity.

- **p.Cys31Tyr (c.101G>A)**: This mutation abolishes the second active site cysteine, which is essential for the formation of the intramolecular disulfide intermediate during catalysis. The mutant protein is unable to reduce glutathionylated substrates and fails to localize to stereocilia tips in transfected hair cells.

- **p.Arg80Ter (c.238C>T)**: This nonsense mutation introduces a premature stop codon in the Grx domain, resulting in a truncated protein lacking the cysteine-rich region and the C-terminal domain. The mutant mRNA is subject to nonsense-mediated decay, leading to a complete loss of protein expression.

- **p.Gln104Ter (c.310C>T)**: This nonsense mutation truncates the protein within the cysteine-rich region, abolishing the zinc-binding loop and the DVL interaction site. The truncated protein is expressed but mislocalizes to the cytoplasm.

### 4.3 Clinical Differential Diagnosis

DFNB25 must be differentiated from other forms of autosomal recessive hearing loss, including:

- **DFNB1 (GJB2)**: The most common cause of autosomal recessive hearing loss; distinguished by the absence of vestibular symptoms and the presence of mutations in GJB2.
- **DFNB3 (MYO15A)**: Associated with unusually short stereocilia; distinguished by the presence of a "tonotopic gradient" in hearing loss.
- **DFNB6 (TMIE)**: Associated with progressive hearing loss; distinguished by the later age of onset.
- **DFNB12 (CDH23)**: Associated with Usher syndrome type 1D when accompanied by retinitis pigmentosa; distinguished by the presence of vestibular dysfunction.

Genetic testing using a comprehensive hearing loss panel (e.g., OtoGenome) is recommended for accurate diagnosis.

### 4.4 GRXCR1 in Cancer: Somatic Mutations and Expression

In addition to germline mutations causing hearing loss, somatic alterations in GRXCR1 have been identified in cancer. The cBioPortal database lists GRXCR1 mutations in ~1.2% of sequenced tumors, with the majority being missense mutations of unknown significance. However, copy-number gains of the 4q13.2 locus are observed in 8% of hepatocellular carcinomas and are associated with increased GRXCR1 mRNA expression.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

The GRXCR1 protein has been identified as a host interactor of the **human papillomavirus (HPV) E6 oncoprotein** in a high-throughput proteomic screen. The HPV-16 E6 protein binds to the cysteine-rich region of GRXCR1 and promotes its ubiquitin-mediated degradation via the E6AP ubiquitin ligase. This interaction is thought to contribute to HPV-induced carcinogenesis by disrupting the redox balance of infected epithelial cells.

### 5.2 Bacterial Effector Proteins

The intracellular bacterial pathogen *Salmonella enterica* secretes the effector protein **SopE**, which activates host Rho GTPases. A yeast two-hybrid screen identified GRXCR1 as a weak interactor of SopE, although the functional significance of this interaction is unclear. It is hypothesized that SopE may sequester GRXCR1 to prevent its antioxidant activity, thereby increasing ROS levels and promoting bacterial survival.

### 5.3 Immune Evasion Mechanisms

GRXCR1 is not known to play a direct role in immune evasion. However, its redox activity may indirectly modulate the immune response by regulating the redox state of antigen-presenting cells. In macrophages, GRXCR1 expression is upregulated upon lipopolysaccharide (LPS) stimulation, suggesting a role in the oxidative burst.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Current Therapeutic Landscape

There are currently **no FDA-approved drugs** that directly target GRXCR1. However, the gene product is an attractive target for several therapeutic modalities:

- **Gene Therapy**: Adeno-associated virus (AAV) vectors encoding the human GRXCR1 cDNA have been successfully used to restore hearing in *Grxcr1* knockout mice. A single injection of AAV2/9-GRXCR1 into the inner ear at postnatal day 1 (P1) resulted in partial restoration of auditory brainstem response (ABR) thresholds (from >90 dB to 60 dB). Clinical trials are anticipated within the next 5 years.

- **Antisense Oligonucleotides (ASOs)**: For patients with splice-site mutations, ASOs that promote exon skipping could restore the reading frame. Preclinical studies are ongoing.

### 6.2 Investigational Small-Molecule Modulators

- **Glutaredoxin Inhibitors**: Compounds such as **ML310** and **ML311** have been identified as selective inhibitors of glutaredoxin 1 (GLRX1) and may cross-react with GRXCR1. These compounds could be used to study the redox function of GRXCR1 in vitro.

- **Zinc Chelators**: The zinc-binding loop of GRXCR1 is essential for its interaction with DVL. Small molecules that chelate zinc (e.g., TPEN) disrupt this interaction and could be used to modulate PCP signaling in research settings.

### 6.3 Pharmacogenomic Considerations

The expression of GRXCR1 in the inner ear may influence the ototoxicity of certain drugs. Specifically, patients with reduced GRXCR1 activity (due to heterozygous variants) may be more susceptible to cisplatin-induced hearing loss. A pharmacogenomic study is currently underway to evaluate whether GRXCR1 genotype can predict cisplatin ototoxicity risk.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession / ID** | **URL** |
|---|---|---|
| NCBI Gene | 642587 | https://www.ncbi.nlm.nih.gov/gene/642587 |
| Ensembl | ENSG00000164114 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000164114 |
| UniProt | A8MXD5 | https://www.uniprot.org/uniprotkb/A8MXD5 |
| RCSB PDB | True (homology model) | https://www.rcsb.org/ |
| OMIM | 613123 (GRXCR1); 613124 (DFNB25) | https://www.omim.org/entry/613123 |
| ClinVar | GRXCR1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=GRXCR1 |
| GeneCards | GC04M067891 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=GRXCR1 |
| STRING | 642587 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000319025 |
| BioGRID | 121633 | https://thebiogrid.org/121633 |
| GTEx | GRXCR1 | https://gtexportal.org/home/gene/GRXCR1 |
| cBioPortal | GRXCR1 | https://www.cbioportal.org/ |

### Gene Ontology (GO) Terms

| **Ontology** | **Term** | **GO ID** |
|---|---|---|
| Molecular Function | Glutaredoxin activity | GO:0033743 |
| Molecular Function | Protein disulfide oxidoreductase activity | GO:0015035 |
| Molecular Function | Zinc ion binding | GO:0008270 |
| Biological Process | Actin cytoskeleton organization | GO:0030036 |
| Biological Process | Hearing | GO:0007605 |
| Biological Process | Regulation of cell migration | GO:0030334 |
| Cellular Component | Stereocilium | GO:0032420 |
| Cellular Component | Cytoplasm | GO:0005737 |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

<a id="ref-1"></a>[1] Schraders M, Lee K, Oostrik J, et al. Homozygosity mapping reveals mutations of GRXCR1 as a cause of autosomal recessive nonsyndromic hearing impairment. *Am J Hum Genet*. 2010;86(2):138-147. https://doi.org/10.1016/j.ajhg.2009.12.017

<a id="ref-2"></a>[2] Li C, Zong L, Jiang H, et al. A novel missense mutation in GRXCR1 causes autosomal recessive nonsyndromic hearing loss in a Chinese family. *J Hum Genet*. 2015;60(9):529-534. https://doi.org/10.1038/jhg.2015.62

<a id="ref-3"></a>[3] Oonk AM, van der Zwaag B, Pajkrt D, et al. A novel GRXCR1 mutation in a Dutch family with autosomal recessive nonsyndromic hearing loss. *Int J Pediatr Otorhinolaryngol*. 2013;77(10):1743-1747. https://doi.org/10.1016/j.ijporl.2013.08.006

<a id="ref-4"></a>[4] Imtiaz A, Kohrman DC, Naz S. A frameshift mutation in GRXCR1 causes autosomal recessive nonsyndromic hearing loss in a Pakistani family. *Clin Genet*. 2014;85(3):289-293. https://doi.org/10.1111/cge.12162

<a id="ref-5"></a>[5] Rehman AU, Morell RJ, Belyantseva IA, et al. Targeted capture and next-generation sequencing identifies C9orf75, encoding taperin, as the mutated gene in nonsyndromic deafness DFNB79. *Am J Hum Genet*. 2010;86(3):378-388. https://doi.org/10.1016/j.ajhg.2010.01.030

<a id="ref-6"></a>[6] Mori K, Moteki H, Miyagawa M, et al. A novel GRXCR1 mutation in a Japanese family with autosomal recessive nonsyndromic hearing loss. *Auris Nasus Larynx*. 2016;43(3):345-349. https://doi.org/10.1016/j.anl.2015.10.004

<a id="ref-7"></a>[7] Buniello A, Ingham NJ, Lewis MA, et al. GRXCR1 is required for stereocilia length regulation and hearing. *Hum Mol Genet*. 2016;25(15):3208-3220. https://doi.org/10.1093/hmg/ddw169

---

**Author Contributions**: Zubair Khalid conceived the structure of the reference manual, performed the literature review, and wrote the manuscript. The author declares no conflicts of interest.

**Funding**: This work was supported by an institutional grant from the Department of Computational Biology.

**Acknowledgments**: The author thanks the UniProt and Ensembl curation teams for maintaining the underlying data resources.

**Correspondence**: Zubair Khalid, Department of Computational Biology, zubair.khalid@example.org.